Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Provention Bio (PRVB)
NASDAQ:PRVB
Holding PRVB?
Track your performance easily
See the Price Targets and Ratings of:
PRVB Analyst Ratings
Moderate Buy
2 Buy
4 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
PRVB Stock 12 Month Forecast
Average Price Target
$25.00
▲(0.08% Upside)
| Highest Price Target$25.00 | Average Price Target$25.00 | Lowest Price Target$25.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$25
Hold
0.08%
Upside
Downgraded
03/15/23
H.C. Wainwright downgrades Provention Bio (PRVB) to a Hold
Chardan Capital
$25
Buy
0.08%
Upside
Reiterated
03/13/23
Analysts Are Bullish on These Healthcare Stocks: HCA Healthcare (HCA), Provention Bio (PRVB)
SVB Securities
―
Buy
―
Reiterated
03/13/23
We also see low likelihood of an emerging competing bid, as Sanofi has the best visibility into the ongoing launch and commercial dynamics of Tzield given the co-promote collaboration. Overall, we believe the PRVB acquisition is a reasonable strategic fit for Sanofi, as the company continues to expand its focus on innovative immunology and disease-modifying therapeutics, combined with its expertise & commercial presence in metabolic disease and the existing partnership. In our view, the strong premium ahead of the PROTECT trial readout in 2H23 speaks to Sanofi's confidence in the commercial outlook for Tzield in the at-risk T1D population, as well as confidence in the clinical execution and potential for Tzield in the broader newly diagnosed T1D indication.
Cantor Fitzgerald
$25
Hold
0.08%
Upside
Downgraded
03/13/23
Provention Bio downgraded to Neutral from Overweight at Cantor FitzgeraldProvention Bio downgraded to Neutral from Overweight at Cantor Fitzgerald
Jefferies
$25
Hold
0.08%
Upside
Downgraded
03/13/23
Provention Bio (PRVB) downgraded to Hold from Buy at Jefferies
SMBC Nikko
$25
Hold
0.08%
Upside
Downgraded
03/13/23
Provention Bio downgraded to Neutral from Outperform at SMBC NikkoProvention Bio downgraded to Neutral from Outperform at SMBC Nikko
Oppenheimer
$18
Buy
-27.94%
Downside
Reiterated
11/18/22
Oppenheimer Maintains Outperform on Provention Bio, Raises Price Target to $18
RBC Capital
$9
Hold
-63.97%
Downside
Reiterated
11/18/22
RBC Capital on Provention Bio Inc. (PRVB): we believe an approval has already been priced in and we watch for the durability of share levelsRBC Capital analyst Gregory Renza reiterated a Sector Perform rating and $9.00 price target on Provention Bio Inc. (NASDAQ: PRVB)
PRVB Analyst Recommendation Trends
Currently, no data available
Please return soon. This page is being updated.
Each month's total comprises the sum of three months' worth of ratings.
PRVB Financial Forecast
PRVB Stock Forecast FAQ
What is PRVB’s average 12-month price target, according to analysts?
Based on analyst ratings, Provention Bio’s 12-month average price target is $25.00.
What is PRVB’s upside potential, based on the analysts’ average price target?
Provention Bio has 0.08% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is PRVB a Buy, Sell or Hold?
Provention Bio has a consensus rating of Moderate Buy which is based on 2 buy ratings, 4 hold ratings and 0 sell ratings.
What is Provention Bio’s price target?
The average price target for Provention Bio is $25.00. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $25.00 ,the lowest forecast is $25.00. The average price target represents 0.08% Increase from the current price of $24.98.
The highest analyst price target is $25.00 ,the lowest forecast is $25.00. The average price target represents 0.08% Increase from the current price of $24.98.
What do analysts say about Provention Bio?
Provention Bio’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
How can I buy shares of PRVB?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.